Larotrectinib
HealthData.Gov
Updated Jun 12, 2026
About this dataset
Vitrakvi (larotrectinib) is an oral solution that inhibits tropomyosin receptor kinases, prescribed for certain cancers with NTRK gene fusions. It's a 20 mg/mL concentrate manufactured by Bayer HealthCare Pharmaceuticals Inc. and approved under NDA211710 in December 2022. This information was generated using AI and is provided for informational and research purposes only.
Data and resources (1)
- HTML
Larotrectinib
Access the FDA dataset for Larotrectinib â ANDA 203308 submitted by Mylan Institutional LLC
Modified Dec 27, 2025